| CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy TJ Fry, NN Shah, RJ Orentas, M Stetler-Stevenson, CM Yuan, ... Nature medicine 24 (1), 20-28, 2018 | 1405 | 2018 |
| Tumor antigen escape from CAR T-cell therapy RG Majzner, CL Mackall Cancer discovery 8 (10), 1219-1226, 2018 | 973* | 2018 |
| c-Jun overexpression in CAR T cells induces exhaustion resistance RC Lynn, EW Weber, E Sotillo, D Gennert, P Xu, Z Good, H Anbunathan, ... Nature 576 (7786), 293-300, 2019 | 720 | 2019 |
| GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas RG Majzner, S Ramakrishna, KW Yeom, S Patel, H Chinnasamy, ... Nature 603 (7903), 934-941, 2022 | 602 | 2022 |
| CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors RG Majzner, JL Theruvath, A Nellan, S Heitzeneder, Y Cui, CW Mount, ... Clinical Cancer Research 25 (8), 2560-2574, 2019 | 561 | 2019 |
| Clinical lessons learned from the first leg of the CAR T cell journey RG Majzner, CL Mackall Nature medicine 25 (9), 1341-1355, 2019 | 550 | 2019 |
| Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling EW Weber, KR Parker, E Sotillo, RC Lynn, H Anbunathan, J Lattin, ... Science 372 (6537), eaba1786, 2021 | 483 | 2021 |
| Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas CW Mount, RG Majzner, S Sundaresh, EP Arnold, M Kadapakkam, ... Nature medicine 24 (5), 572-579, 2018 | 479 | 2018 |
| CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial JY Spiegel, S Patel, L Muffly, NM Hossain, J Oak, JH Baird, MJ Frank, ... Nature medicine 27 (8), 1419-1431, 2021 | 467 | 2021 |
| Tuning the Antigen Density Requirement for CAR T Cell Activity RG Majzner, SP Rietberg, E Sotillo, R Dong, VT Vachharajani, ... Cancer Discovery, 2020 | 451 | 2020 |
| Programming CAR-T cells to kill cancer L Labanieh, RG Majzner, CL Mackall Nature biomedical engineering 2 (6), 377-391, 2018 | 408 | 2018 |
| Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase AJ Walker, RG Majzner, L Zhang, K Wanhainen, AH Long, SM Nguyen, ... Molecular Therapy 25 (9), 2189-2201, 2017 | 374 | 2017 |
| Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours CL Flugel, RG Majzner, G Krenciute, G Dotti, SR Riddell, DL Wagner, ... Nature Reviews Clinical Oncology 20 (1), 49-62, 2023 | 250 | 2023 |
| Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors J Theruvath, E Sotillo, CW Mount, CM Graef, A Delaidelli, S Heitzeneder, ... Nature medicine 26 (5), 712-719, 2020 | 245 | 2020 |
| Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication J Theruvath, M Menard, BAH Smith, MH Linde, GL Coles, GN Dalton, ... Nature medicine 28 (2), 333-344, 2022 | 172 | 2022 |
| Assessment of programmed death‐ligand 1 expression and tumor‐associated immune cells in pediatric cancer tissues RG Majzner, JS Simon, JF Grosso, D Martinez, BR Pawel, M Santi, ... Cancer 123 (19), 3807-3815, 2017 | 169 | 2017 |
| Novel NanoLuc substrates enable bright two-population bioluminescence imaging in animals Y Su, JR Walker, Y Park, TP Smith, LX Liu, MP Hall, L Labanieh, R Hurst, ... Nature Methods 17 (8), 852-860, 2020 | 167 | 2020 |
| CAR T cell therapy for neuroblastoma RM Richards, E Sotillo, RG Majzner Frontiers in immunology 9, 2380, 2018 | 164 | 2018 |
| Enhanced safety and efficacy of protease-regulated CAR-T cell receptors L Labanieh, RG Majzner, D Klysz, E Sotillo, CJ Fisher, JG Vilches-Moure, ... Cell 185 (10), 1745-1763. e22, 2022 | 158 | 2022 |
| Harnessing the immunotherapy revolution for the treatment of childhood cancers RG Majzner, S Heitzeneder, CL Mackall Cancer cell 31 (4), 476-485, 2017 | 155 | 2017 |
Crystal MackallStanford UniversityE-mail megerősítve itt: stanford.edu
